A study to investigate subcutaneous isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma

Trial Identifier: ACT17453
Sponsor: Sanofi
Start Date: April 2023
Primary Completion Date: December 2025
Study Completion Date: May 2028
Condition: Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AUSTRALIA, New South Wales WOLLONGONG, New South Wales, AUSTRALIA, 2500
AUSTRALIA, Victoria MELBOURNE, Victoria, AUSTRALIA, 3065
BRAZIL, Rio Grande do Sul PORTO ALEGRE, Rio Grande do Sul, BRAZIL, 90880-480
BRAZIL, São Paulo SÃO PAULO, São Paulo, BRAZIL, 04537-080
BRAZIL, São Paulo SÃO PAULO, São Paulo, BRAZIL, 05403-000
CHINA CHANGSHA, CHINA, 410013
CHINA GUANGZHOU, CHINA, 510060
CHINA NANCHANG, CHINA, 330006
CHINA SHENYANG, CHINA, 110004
CHINA TIANJIN, CHINA, 300020
CHINA TIANJIN, CHINA, 300060
CHINA Wuhan, CHINA, 430030
CZECHIA BRNO, CZECHIA, 625 00
CZECHIA OLOMOUC, CZECHIA, 779 00
CZECHIA OSTRAVA, CZECHIA, 708 52
CZECHIA PRAGUE, CZECHIA, 128 08
GREECE ATHENS, GREECE, 106 76
GREECE ATHENS, GREECE, 115 28
JAPAN, Chiba KASHIWA, Chiba, JAPAN, 277-8577
JAPAN, Okayama OKAYAMA, Okayama, JAPAN, 701-1192
PORTUGAL Braga, PORTUGAL, 4710-243
PORTUGAL LISBON, PORTUGAL, 1400-038
PORTUGAL LISBON, PORTUGAL, 1649-035